March 15, 2016
Summit Therapeutics plc (NASDAQ: SMMT LON:SUMM) has identified biomarkers to relate muscle regeneration and the presence of utrophin protein in patients with Duchenne (DMD) and Becker muscular dystrophy (BMD). DMD is caused by the absence of dystrophin protein and it is believed utrophin modulation, a naturally occurring protein similar to dystrophin, could slow or even stop the […]
March 14, 2016
from PR Newswire
SOUTH PLAINFIELD, N.J., March 14, 2016 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company intends to submit the results of the recently completed Phase 3 ACT DMD study for review by Health Canada as part of the New Drug Submission (NDS) for Translarna™ (ataluren) to treat nonsense mutation Duchenne muscular dystrophy (nmDMD). In order to […]
March 4, 2016
Neuromuscular specialists supporting adults with Duchenne muscular dystrophy from across the UK came together this week to take the first steps in the creation of new standards of care for adults living with Duchenne. Click here to read more.
January 14, 2016
from AM980
Jesse’s Journey is applauding Wednesday’s announcement the federal government will help fund a stem cell therapy development facility in Toronto. Prime Minister Justin Trudeau said the government will provide $20 million to the Centre for Commercialization of Regenerative Medicine. Trudeau said supporting the facility will have significant benefits for innovative, health-related technology in Canada and […]
January 14, 2016
from Bloomberg Business
BioMarin Pharmaceutical Inc. failed to win U.S. approval for a drug to treat Duchenne muscular dystrophy, a deadly genetic disease that usually affects young boys. The Food and Drug Administration rejected the once-a-week injection known as Kyndrisa, according to a statement from the company Thursday. A panel of outside advisers voted in November that the medication, known chemically […]
January 13, 2016
from The Globe and Mail
The federal government will provide $20 million to the Centre for Commercialization of Regenerative Medicine to help establish a stem-cell therapy development facility in Toronto. The Centre for Advanced Therapeutic Cell Technologies will be the first such facility in the world to use a collaborative approach between research institutions and industry to solve cell therapy […]
January 8, 2016
from PR Newswire
SOUTH PLAINFIELD, N.J., Jan. 8, 2016 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the completion of its rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for Translarna™ (ataluren), an oral, first-in-class, protein restoration therapy for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). PTC has also […]
January 6, 2016
from EurekAlert
A drug commonly used to treat leukaemia is showing potential as a treatment that could slow the progression of the muscle-wasting condition, Duchenne muscular dystrophy. Duchenne muscular dystrophy most commonly affects boys, with around 2,400 people in the UK affected by the condition. There is currently no cure and most patients are not expected to […]
December 31, 2015
from UT Southwestern Medical Centre
DALLAS – Dec. 31, 2015 – Using a new gene-editing technique, a team of scientists from UT Southwestern Medical Center stopped progression of Duchenne muscular dystrophy (DMD) in young mice. If efficiently and safely scaled up in DMD patients, this technique could lead to one of the first successful genome editing-based treatments for this fatal […]
